• Recruiting

NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma

Updated: Jul 12

NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma


APG-2575

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma


This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG2575 monotherapy or in combination with lenalidomide (R) and dexamethasone (d) in patients with relapsed/refractory (R/R) multiple myeloma (MM). The primary objective is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT), the maximum tolerated dose (MTD) and the recommended dose (RP2D) of APG-2575 monotherapy or in combination with Rd in Chinese R/R MM patients.


Sponsor

Ascentage Pharma Group Inc


Location

China

 

ClinicalTrials.gov Identifier: NCT04674514


Official Title: Phase Ib / II Open-Label Stduy of APG-2575 Monotherapy or in Combination With Lenalidomide / Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma


First Posted: December 19, 2020


Click here for details on ClinicalTrials.gov

 

Drug: APG-2575

Drug: Rd

 

APG 2575

Lisaftoclax (Code C156249)

APG 2575

APG-2575

APG2575

Bcl-2 Inhibitor APG 2575

Lisaftoclax

LISAFTOCLAX

 

Locations

China, Beijing

China, Guangdong

China, Henan

China, Hubei

China, Jiangsu

China, Zhejiang



Posts Archive